Therefore, the disruption of this glycolytic pathway has become a major area of focus in the development of novel anti-cancer drugs, as exemplified by those strategies aimed at inhibiting key rate-limiting glycolytic regulatory enzymes, including hexokinase 2 (HK2), phosphofructokinase (PFK), or pyruvate kinase M2 (PKM2) (Scatena et al., 2008; Ganapathy-Kanniappan and Geschwind, 2013). This evidence concerns the gene PKM and cancer.